https://www.ladanuzhna.xyz/writing daily 1.0 2025-08-31 https://www.ladanuzhna.xyz/writing/trillion-dollar-biotechs monthly 0.5 2025-08-31 https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/3c578b55-452b-4aad-b48b-d13b9e88e457/Screenshot+2025-08-31+at+10.34.44%E2%80%AFAM.png Various - Where are all the trillion dollar biotechs? - Make it stand out Src: EvaluatePharma, IRR analysis https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/505a29c9-959e-4004-981e-a63a41a081fd/Screenshot+2025-08-31+at+10.58.15%E2%80%AFAM.png Various - Where are all the trillion dollar biotechs? - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/01c46740-a332-4ce4-b3d8-461e3c2a378a/Screenshot+2025-08-31+at+11.02.18%E2%80%AFAM.png Various - Where are all the trillion dollar biotechs? - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/63ec5a8f-8c00-429b-b824-bce7bb27ee2f/Screenshot+2025-08-31+at+10.50.34%E2%80%AFAM.png Various - Where are all the trillion dollar biotechs? - After spending 33 years in development and trials, and approving 3 drugs for devastating rare disorders, Bluebird Bio was acquired for a mere $30 million – that’s less than the $120 million raised by Juicero, an infamous startup that manufactured machines for squeezing juices out of bags. After spending 33 years in development and trials, and approving 3 drugs for devastating rare disorders, Bluebird Bio was acquired for a mere $30 million – that’s less than the $120 million raised by Juicero, an infamous startup that manufactured machines for squeezing juices out of bags. https://www.ladanuzhna.xyz/writing/just-how-bad-are-we-at-treating-age-related-diseases monthly 0.5 2025-06-15 https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/715e47a7-894c-4b8c-85dc-defba5b1c6ab/Screenshot+2024-09-28+at+8.26.47+PM.png Various - Just how bad are we at treating age-related diseases? - Donanemab TRAILBLAZER-ALZ 2 Phase 3 trial Primary endpoint is CDR (Clinical Dementia Rating) which measures orientation, memory, problem-solving, interactions with the community, and home life 28.9% slowing (95% CI, 18.41%-39.44%) of clinical progression in the primary end point https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/12e5d5ee-5f0c-4db8-abc6-347077699b41/Screenshot+2024-09-28+at+8.11.52+PM.png Various - Just how bad are we at treating age-related diseases? - SYFOVRE™ (pegcetacoplan) OAK & DERBY Phase 3 trial data Primary endpoint focused on lesion growth https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/9f4432ec-baa7-4bec-b909-3f9ffe41b445/Screenshot+2024-09-28+at+8.18.55+PM.png Various - Just how bad are we at treating age-related diseases? - Izervay (ACP) GATHER 1 & GATHER 2 Phase 3 data Primary endpoint focused on lesion growth https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/d2fb9c52-1881-4f9f-809e-59bdddee8515/Screenshot+2024-09-28+at+8.13.45+PM.png Various - Just how bad are we at treating age-related diseases? - Same treatment, showing no statistically significant improvements in vision (BCVA) https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/f7f18a1a-6160-4181-962f-3eadc8191c51/Screenshot+2024-09-28+at+8.20.40+PM.png Various - Just how bad are we at treating age-related diseases? - Pirfenidone, CAPACITY trial The primary endpoint is forced vital capacity (FVC) No improvement in the primary endpoint relative to the placebo in STUDY 006 of the CAPACITY Trial (Fig B) https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/d9879d60-3389-4e96-a906-b6ca3158cd09/Screenshot+2024-09-28+at+8.21.18+PM.png Various - Just how bad are we at treating age-related diseases? - Nintedanib, Phase 3 INPULSIS 1 & 2: Primary endpoint is forced vital capacity (FVC) https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/2eedde98-4c72-47e6-acf3-4de6830948be/Screenshot+2024-09-28+at+8.25.46+PM.png Various - Just how bad are we at treating age-related diseases? - Lecanemab Phase 3 trial Primary endpoint is CDR (Clinical Dementia Rating) which measures orientation, memory, problem-solving, interactions with the community, and home life https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/1df415b2-66d6-4b10-9bec-7d95a6fe018c/Screenshot+2024-09-28+at+8.19.36+PM.png Various - Just how bad are we at treating age-related diseases? - Izervay, with no improvement in vision https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/a348236f-ab95-4182-a8b9-650826bb9fcd/Screenshot+2024-09-28+at+8.22.37+PM.jpg Various - Just how bad are we at treating age-related diseases? - Phase 3 Resmetirom data Primary endpoints: NASH resolution with no worsening of fibrosis (a scoring metric that focuses on metabolic and inflammatory aspects of the disease) and Fibrosis improvement with no worsening of metabolic aspects of the disease (4 stages of fibrosis: F1-F4) https://www.ladanuzhna.xyz/writing/list-of-biotech-founders monthly 0.5 2024-11-02 https://www.ladanuzhna.xyz/writing/the-digital-and-analog-worlds-of-protein-engineering monthly 0.5 2023-08-26 https://www.ladanuzhna.xyz/writing/2-year-of-running-impetus monthly 0.5 2023-07-16 https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/333ae637-84b4-43d0-9875-680ba7cc7e87/Screenshot+2023-07-11+at+10.15.08+AM.png Various - Impetus Grants: reflections on 2 years of going after risky aging science - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/12bdba52-ea85-448a-a92c-177354f85ab4/Screenshot+2023-07-11+at+10.15.23+AM.png Various - Impetus Grants: reflections on 2 years of going after risky aging science - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.ladanuzhna.xyz/writing/aging-field-needs-a-lot-of-policy-work monthly 0.5 2024-11-02 https://www.ladanuzhna.xyz/writing/42-hidden-golden-ratios monthly 0.5 2023-07-16 https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/938d825a-0c16-4a00-9667-4ea76f52d600/Ffr_3PgVQAA8-YN.jpeg Various - 42 hidden golden ratios - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.ladanuzhna.xyz/writing/deep-learning-for-biochem monthly 0.5 2023-07-16 https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/698bf723-78ce-4773-b9aa-f96b71ef8468/Screen+Shot+2022-05-11+at+6.28.19+PM.png Various - So where are we with deep learning for biochem? - Make it stand out Two almost identical molecules have markedly different canonical SMILES with edit distance >50% of the whole sequence; source: https://arxiv.org/abs/1802.04364 https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/ae192d6d-c0bf-429f-be2b-13b95bebba24/Notes+2022-112.jpg Various - So where are we with deep learning for biochem? - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.ladanuzhna.xyz/writing/impetus-grants monthly 0.5 2023-07-16 https://www.ladanuzhna.xyz/writing/what-do-methylation-clocks-need-to-become-biomarkers-in-aging-trials-fxmkb monthly 0.5 2021-10-30 https://www.ladanuzhna.xyz/writing/deep-generative-models-for-drug-design-and-response monthly 0.5 2023-07-16 https://www.ladanuzhna.xyz/writing/generative-adversarial-networks-with-feedback-mechanism-for-novel-protein-sequences monthly 0.5 2023-07-16 https://www.ladanuzhna.xyz/writing/odjo8jpjbb5ec1jail7uzd7h0thr26 monthly 0.5 2023-07-16 https://www.ladanuzhna.xyz/writing/inventing-biology monthly 0.5 2024-11-02 https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/e75d7c89-1d85-422f-bc59-531c4040f5fe/thermalcycler.jpeg Various - Learning to learn from inventions: electrophoresis, PCR, Sanger sequencing - Make it stand out The initial version of PCR managed to exist without thermostable polymerase and was implemented as a machine called "Mr.Cycle.” src:https://americanhistory.si.edu/collections/search/object/nmah_1000862 https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/4e2a9736-81a3-4814-87b7-0eee2c241492/Screen+Shot+2021-11-16+at+11.52.17+AM.png Various - Learning to learn from inventions: electrophoresis, PCR, Sanger sequencing - Make it stand out Electrophoretic machine as designed by Tiselius https://images.squarespace-cdn.com/content/v1/617c9787b3135121fdb3bf46/2924c3ff-90f1-46e4-a978-b2905c6b6014/Screen+Shot+2021-11-16+at+11.37.53+AM.png Various - Learning to learn from inventions: electrophoresis, PCR, Sanger sequencing - Make it stand out Notebook of Mullis with his attempt to run PCR reaction src:https://www.the-scientist.com/foundations-old/the-first-polyullmerase-chain-reaction-52020 https://www.ladanuzhna.xyz/writing/tag/art monthly 0.5 https://www.ladanuzhna.xyz/writing/tag/science monthly 0.5 https://www.ladanuzhna.xyz/writing/tag/aging monthly 0.5 https://www.ladanuzhna.xyz/writing/tag/policy monthly 0.5